Receive CohnReznick insights and event invitations on topics relevant to your business and role.
10/22/2018
Life Sciences IPO Market Remains Consistently Strong in 2018, With Q3 No Exception
.jpg?h=630&iar=0&w=1200&hash=D4BF4570E2B13AACFB566F8B11BA8F73)
Life sciences with biotech companies paving the way represent a significant portion of IPOs in 2018. The sector continued to attract investor dollars in Q3, and is No. 1 in the deal-count category with 20, representing $1.51 billion in capital invested.
In this PDF, we quantify Q3 IPO activity in life sciences, and compare YTD with last year. There is no reason to believe that life sciences’ momentum has peaked, because IPOs in the industry continue to offer significant returns.
Ravi Raghunathan
CPA, Partner - Life Sciences Industry Leader
Close
Contact
Let’s start a conversation about your company’s strategic goals and vision for the future.
Please fill all required fields*
Please verify your information and check to see if all require fields have been filled in.
Growth Begins with New Ideas: Attend our virtual events, webinars, and discussion forums.
Related services
This has been prepared for information purposes and general guidance only and does not constitute legal or professional advice. You should not act upon the information contained in this publication without obtaining specific professional advice. No representation or warranty (express or implied) is made as to the accuracy or completeness of the information contained in this publication, and CohnReznick LLP, its partners, employees and agents accept no liability, and disclaim all responsibility, for the consequences of you or anyone else acting, or refraining to act, in reliance on the information contained in this publication or for any decision based on it.